摘要
背景:痴呆症发展过程中脑血管疾病(CVD)病理与阿尔茨海默氏病(AD)病理之间的相互作用是有争议的。我们检查了脑血管神经病理学和脑血管危险因素与阿尔茨海默氏症痴呆的轻度阶段和认知功能的关系。 方法:这项横断面研究包括60岁或60岁以上的男性和女性,他们接受了年度临床评估并且同意在死亡时进行脑部尸检,并且为美国国家阿尔茨海默氏症协调中心(NACC)中存储的数据做出了贡献。我们的分析包括认知功能正常和受损的受试者,这些受试者具有AD的推测病因,包括轻度认知障碍(ADMCI)和痴呆症(阿尔茨海默氏痴呆症),并具有完整的神经病理学数据。我们使用了濒临死亡的神经心理学数据来创建全球认知和认知领域的汇总指标。系统神经病理学评估记录了脑血管病理的严重程度。对死亡年龄,性别和路易体病理进行校正的逻辑和线性回归分析分别用于检查血管疾病与阿尔茨海默氏病痴呆的严重程度和认知功能的相关性。 结果:晚期危险因素与阿尔茨海默氏痴呆症之间未发现显着相关性。动脉硬化的严重程度和整体梗塞/腔隙的存在与轻度阿尔茨海默氏痴呆症相关(B = 0.423,p <0.001; B = 0.366,p = 0.026),并且在调整了神经斑和神经原纤维缠结后效果显着(B = 0.385,p <0.001; B = 0.63,p = 0.001)。当将血管性脑损伤分为旧型和急性/亚急性型时,我们发现旧的微梗塞和旧的微出血与轻度阿尔茨海默氏痴呆症有关(B = 0.754,p = 0.007; B = 2.331,p = 0.032)。纠正AD病变后,旧的微梗塞仍然与轻度的阿尔茨海默氏痴呆症显着相关(B = 1.31,p <0.001)。此外,大脑皮层中的微梗塞数量与轻度的阿尔茨海默氏痴呆症有显着相关性,无论数据是否针对AD病理进行了校正(B = 0.616,p = 0.016; B = 0.884,p = 0.005)。发现动脉粥样硬化,动脉硬化和白质稀疏与阿尔茨海默氏痴呆症的更快进展显着相关(B = 0.068,p = 0.001; B = 0.046,p = 0.016,B = 0.081,p = 0.037),但白质稀疏在调整了AD病理之后,在更长的时间产生了显着影响。我们还发现,动脉粥样硬化的严重程度与加工速度(β= -0.112,p = 0.006)和执行功能(β= -0.092,p = 0.023)受损有关。动脉硬化与语言(β= -0.103,p = 0.011)和整体认知(β= -0.098,p = 0.016)缺陷显着相关。 结论:我们的研究发现,阿尔茨海默氏痴呆症的发作和严重程度与总体,旧的,急性/亚急性和区域性脑血管病变(而不是白质稀疏)有显着关系。我们还表明,发现晚期风险因素与阿尔茨海默氏痴呆症无关,并且APOEε4导致痴呆症的风险增加不是由CVD介导的。这些发现的最好解释是,CVD在临床诊断为阿尔茨海默氏痴呆症的发生和发展中与AD病理学具有潜在的加和作用。
关键词: 脑血管病理学,阿尔茨海默氏病,阿尔茨海默氏痴呆症,认知,神经退行性疾病,淀粉样斑块。
Current Alzheimer Research
Title:The Contribution of Cerebral Vascular Neuropathology to Mild Stage of Alzheimer’s Dementia Using the NACC Database
Volume: 17 Issue: 13
关键词: 脑血管病理学,阿尔茨海默氏病,阿尔茨海默氏痴呆症,认知,神经退行性疾病,淀粉样斑块。
摘要:
Background: The interaction between cerebral vessel disease (CVD) pathology and Alzheimer’s disease (AD) pathology in the development of dementia is controversial. We examined the association of cerebral vascular neuropathology and cerebrovascular risk factors with the mild stage of Alzheimer's dementia and cognitive function.
Methods: This cross-sectional study included men and women aged 60 years or over who had yearly clinical assessments and had agreed to brain autopsy at the time of death, and who contributed to data stored at the National Alzheimer's Coordinating Center (NACC) in the USA. Cognitively normal and impaired subjects with presumptive aetiology of AD, including mild cognitive impairment (ADMCI) and dementia (Alzheimer’s dementia), and with complete neuropathological data, were included in our analyses. We used neuropsychological data proximate to death to create summary measures of global cognition and cognitive domains. Systematic neuropathological assessments documenting the severity of cerebral vascular pathology were included. Logistic and linear regression analyses corrected for age at death, sex and Lewy body pathology were used to examine associations of vessel disease with the severity of Alzheimer's disease dementia, and cognitive function, respectively.
Results: No significant relationship was observed between late-life risk factors and Alzheimer’s dementia. The severity of arteriosclerosis and presence of global infarcts/lacunes were related to mild Alzheimer’s dementia (B=0.423, p<0.001; B=0.366, p=0.026), and the effects were significant after adjusting for neuritic plaques and neurofibrillary tangles (B=0.385, p<0.001; B=0.63, p=0.001). When vascular brain injuries were subdivided into old and acute/subacute types, we found that old microinfarcts and old microbleeds were associated with mild Alzheimer’s dementia (B=0.754, p=0.007; B=2.331, p=0.032). The old microinfarcts remained significantly associated with mild Alzheimer’s dementia after correcting AD pathologies (B=1.31, p<0.001). In addition, the number of microinfarcts in the cerebral cortex had a significant relation with mild Alzheimer’s dementia, whether or not the data were corrected for AD pathologies (B=0.616, p=0.016; B=0.884, p=0.005). Atherosclerosis, arteriosclerosis and white matter rarefaction were found to be significantly associated with faster progression of Alzheimer’s dementia (B=0.068, p=0.001; B=0.046, p=0.016, B=0.081, p=0.037), but white matter rarefaction no longer had a significant effect after adjusting for AD pathologies. We also found that the severity of atherosclerosis was related to impairment in processing speed (β=-0.112, p=0.006) and executive function (β=-0.092, p=0.023). Arteriosclerosis was significantly associated with language (β=-0.103, p=0.011) and global cognition (β=-0.098, p=0.016) deficits.
Conclusion: Our study found the significant relation of global, old, acute/subacute and regional cerebral vascular pathologies, but not white matter rarefaction, to the onset and severity of Alzheimer’s dementia. We also showed that late-life risk factors were found to have no relation with Alzheimer’s dementia, and the increased risk of dementia with APOE ε4 is not mediated by CVD. The best interpretation of these findings is that CVD has a potential additive effect with AD pathologies in the development and progression of what is clinically diagnosed as Alzheimer's dementia.
Export Options
About this article
Cite this article as:
The Contribution of Cerebral Vascular Neuropathology to Mild Stage of Alzheimer’s Dementia Using the NACC Database, Current Alzheimer Research 2020; 17 (13) . https://dx.doi.org/10.2174/1567205018666210212160902
DOI https://dx.doi.org/10.2174/1567205018666210212160902 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Anti-apoE4 Specific Monoclonal Antibody Counteracts the Pathological Effects of apoE4 In Vivo
Current Alzheimer Research Alpha7 Neuronal Nicotinic Receptor: A Pluripotent Target for Diseases of the Central Nervous System
CNS & Neurological Disorders - Drug Targets The Effects of CCRC on Cognition and Brain Activity in aMCI Patients: A Pilot Placebo Controlled BOLD fMRI Study
Current Alzheimer Research Obstructive Sleep Apnea Syndrome and Upper Airway Inflammation
Recent Patents on Inflammation & Allergy Drug Discovery Quantifying Risk: The Role of Absolute and Relative Measures in Interpreting Risk of Adverse Reactions from Product Labels of Antipsychotic Medications
Current Drug Safety Endophenotypes and Biological Markers of Schizophrenia: From Biological Signs of Illness to Novel Treatment Targets
Current Pharmaceutical Design A Review of Clinical Pharmacokinetics and Pharmacodynamics of Galantamine, a Reversible Acetylcholinesterase Inhibitor for the Treatment of Alzheimer s Disease, in Healthy Subjects and Patients
Current Clinical Pharmacology Development of Small-Molecule Inhibitors of Raf
Recent Patents on Anti-Infective Drug Discovery Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy Telomere/Telomerase System: A New Target of Statins Pleiotropic Effect?
Current Vascular Pharmacology Infrared-Spectroscopy: A Non-Invasive Tool for Medical Diagnostics and Drug Analysis
Current Medicinal Chemistry Improvement of Microscopic MR Imaging of Amyloid Plaques with Targeting and Non-Targeting Contrast Agents
Current Medical Imaging Familial Hypercholesterolemia: Update and Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Incidence and Prevalence of Hypothyroidism in Patients Affected by Chronic Heart Failure: Role of Amiodarone
Endocrine, Metabolic & Immune Disorders - Drug Targets Genetic Editing and Pharmacogenetics in Current And Future Therapy Of Neurocognitive Disorders
Current Alzheimer Research Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases
Current Neuropharmacology Small Molecule TGF-beta Mimetics as Potential Neuroprotective Factors
Current Alzheimer Research Alzheimer’s Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function
Current Alzheimer Research Neurogenesis in Alzheimers Disease: A Realistic Alternative to Neuronal Degeneration?
Current Signal Transduction Therapy Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies
Current Pharmaceutical Design